Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002413364 | SCV002721951 | pathogenic | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-06-15 | criteria provided, single submitter | clinical testing | The p.C622* pathogenic mutation (also known as c.1866T>A), located in coding exon 17 of the NF1 gene, results from a T to A substitution at nucleotide position 1866. This changes the amino acid from a cysteine to a stop codon within coding exon 17. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Gene |
RCV003320664 | SCV004025725 | pathogenic | not provided | 2024-05-30 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28961165) |
Baylor Genetics | RCV003470618 | SCV004198267 | pathogenic | Juvenile myelomonocytic leukemia | 2023-10-10 | criteria provided, single submitter | clinical testing | |
Medical Genetics, |
RCV000497140 | SCV000588736 | pathogenic | Neurofibromatosis, type 1 | 2017-02-02 | no assertion criteria provided | clinical testing |